Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

KZKeshu ZhouDZDehui ZouLLLanfang Li

Discussion

Loading...

Member takes

Overview

Subgroup analysis shows improved progression-free survival in patients aged ≥65 with relapsed/refractory non-Hodgkin lymphoma, indicating the efficacy of CAR-T therapy.

Key Points

  • Axi-cel treatment achieved higher progression-free survival in patients aged ≥65, with a rate of 66.7% compared to 59.4% in younger patients.
  • Patients treated with axi-cel demonstrated manageable adverse events, with grade ≥3 neurological events occurring at similar rates (3.9% vs. 2.7%).
  • Data gathered from the Center for International Blood and Marrow Transplantation Research showed the efficacy of axi-cel compared to conventional therapies in older populations.
  • Results indicate a higher best complete response rate of 78.4% in patients aged ≥65 than in younger counterparts, suggesting considerable effectiveness.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d91dhttps://doi.org/10.1182/blood-2025-7230
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial2025
  2. 2Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucel2025
  3. 3Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries2025
  4. 4Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study2025
  5. 5Real-world analysis of axicabtagene ciloleucel (axi-cel) as consolidation therapy following first-line treatment in B-cell lymphoma with high-risk factors2025